Vir Biotechnology's Total Assets for the quarter that ended in Dec. 2023 was $1,919.06 Mil.
During the past 12 months, Vir Biotechnology's average Total Assets Growth Rate was -0.80% per year.
During the past 3 years, the average Total Assets Growth Rate was 29.70% per year.
During the past 5 years, the average Total Assets Growth Rate was 43.20% per year.
During the past 7 years, Vir Biotechnology's highest 3-Year average Total Assets Growth Rate was 137.40%. The lowest was 29.70%. And the median was 43.95%.
The historical data trend for Vir Biotechnology's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Vir Biotechnology's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vir Biotechnology (NAS:VIR) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Dec. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Vir Biotechnology's Asset Turnover for the quarter that ended in Dec. 2023 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Vir Biotechnology Total Assets Related Terms
Thank you for viewing the detailed overview of Vir Biotechnology's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Vir Biotechnology (Vir Biotechnology) Business Description
Vir Biotechnology Inc is a commercial-stage immunology company focused on treating and preventing infectious diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VIR has been successfully added to your 